Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:264926.
doi: 10.1155/2010/264926. Epub 2010 Nov 21.

Autoantibodies to tumor-associated antigens in breast carcinoma

Ettie Piura  1 , Benjamin Piura
Affiliations

Autoantibodies to tumor-associated antigens in breast carcinoma

Ettie Piura et al. J Oncol. 2010.

Abstract

Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identified in the circulation of patients with cancer. This paper will focus on recent knowledge related to circulating AAbs to TAAs in breast carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in breast carcinoma: p53, MUC-1, heat shock proteins (HSP-27, HSP-60, and HSP-90), HER2/neu/c-erb B2, GIPC-1, c-myc, c-myb, cancer-testis antigens (NY-ESO-1), BRCA1, BRCA2, endostatin, lipophilin B, cyclin B1, cyclin D1, fibulin, insulin-like growth factor binding protein 2 (IGFBP-2), topoisomerase II alpha (TOPO2α), and cathepsin D. Measurement of serum AAbs to one specific TAA only is of little value for screening and early diagnosis of breast carcinoma; however, assessment of AAbs to a panel of TAAs may have promising diagnostic potential.

PubMed Disclaimer

References

    1. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of Proteome Research. 2008;7(4):1388–1394. - PubMed
    1. Gagnon A, Kim J-H, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clinical Cancer Research. 2008;14(3):764–771. - PubMed
    1. Koziol JA, Zhang J-Y, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clinical Cancer Research. 2003;9(14):5120–5126. - PubMed
    1. Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology Biomarkers and Prevention. 2003;12(2):136–143. - PubMed
    1. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Research. 2002;62(14):4041–4047. - PubMed